Soluble platinum nanoparticles (Pt NPs) have been prepared by a two‐step procedure involving the reduction of chloroplatinic acid with ethylene glycol/NaOH at 160 °C and subsequent treatment with a THF solution of a tris‐imidazolium tetrafluoroborate at room temperature. The isolated Pt NPs have been characterized by transmission electron microscopy (TEM), high‐resolution transmission electron microscopy (HRTEM), electron diffraction (ED), Energy‐Dispersive X‐ray Spectroscopy (EDS), and elemental analysis. They proved to be efficient and recoverable catalysts for the stereoselective hydrosilylation of internal alkynes in the presence and absence of solvent.

Water-soluble gold nanoparticles prepared in the presence of PEG-tagged tris-imidazolium bromide, containing Au(0) and Au(i) species, are reusable catalysts.

Nickel nanoparticles (Ni NPs) from 10 to 17 nm have been prepared by hydrogenation of Ni(COD)2 (3 bar H2, 70 °C) in the presence of trisimidazolium salts (iodide and tetrafluoroborate). The nanoparticles have been structurally and compositionally characterized by transmission electron microscopy (TEM), high‐resolution (HR) TEM, electron diffraction (ED), energy‐dispersive X‐ray spectroscopy (EDS), X‐ray photoelectron spectroscopy (XPS) and elemental analysis. Magnetic measurements reveal that, as expected, the Ni NPs are superparamagnetic at room temperature. These nanomaterials prove efficient as magnetically recoverable catalysts for the transfer hydrogenation of nitroarenes with hydrazine as hydrogen donor. Their superparamagnetic character also ensures no interparticle aggregation once the external magnetic field is removed.

PEGylated imidazolium (bromide and tetrafluoroborate) and tris-imidazolium (bromide) salts containing triazole linkers have been used as stabilizers for the preparation of water-soluble rhodium(0) nanoparticles by reduction of rhodium trichloride with sodium borohydride in water at room temperature. The nanomaterials have been characterized (Transmission Electron Microscopy, Electron Diffraction, X-ray Photoelectron Spectroscopy, Inductively Coupled Plasma-Optical Emission Spectroscopy). They proved to be efficient and recyclable catalysts for the stereoselective hydrosilylation of internal alkynes, in the presence or absence of solvent, and in the reduction of nitroarenes to anilines with ammonia-borane as hydrogen donor in aqueous medium (1:4 tetrahydrofuran/water).

Background: Background:Venetoclax, a BCL-2 specific inhibitor, used in combination with azacitidine in patients with newly-diagnosed acute myeloid leukemia (AML) who were ineligible for intensive chemotherapy treatment, has shown high response rate and overall survival compared with azacitidine monotherapy (Di Nardo et al. N Engl J Med 2020; 383:617-629). Moreover, Venetoclax in combination with hypomethylating agents or with low-dose cytarabine is being explored in other settings being frequently used in relapsed/refractory (R/R) AML. Aims:Aims: We performed a retrospective study of patients with R/R AML receiving venetoclax combinations in the Catalan Institute of Oncology (ICO) in order to determine the efficacy and safety of the combination. Methods: Methods:We analyze 60 patients diagnosed with R/R AML at 4 hospitals belonging to ICO in Spain, treated with venetoclax (400mg/24h; initial daily dose of 100mg with a 3-day ramp-up to target dose of 400mg) in combination with hypomethylating agents (Azacitidine 75mg/m 2 7/28 days or Decitabine 20mg/m 2 5/28 days) or low-dose cytarabine (20mg/m 2 10/28 days) from May 2019 until December 2021. Event was defined as death, refractoriness to treatment or progressive disease. Results: Results:Characteristics of our cohort are described in table 1. Notably, 31 (52%) patients had high-risk AML according to ELN 2017 classification. Fourteen (23%) patients received venetoclax in combination with decitabine, 34 (57%) patients with azacitidine, and 12 (20%) patients with low-dose cytarabine. The median number of cycles received was 3 (range 1-28), with a median of one cycle to achieve the best response (range: 1-4). Early mortality in the first 30 days was 15% (9 patients), 5 due to progression disease, 2 due to infection and 2 due to clinical worsening. Overall response rate after first cycle (Complete response (CR) + complete response without haematological recovery (CRi) + partial response (PR)) was 58%. Three patients were treated in a molecular-MRD positive status, and all of them achieved molecular response. Six of 19 patients (32%) were transitioned to allogeneic stem cell transplantation (alloSCT). The median event-free survival and overall survival was 5.03 months and 7.2 months, respectively. Response to treatment after 3-4 cycles, discriminate two groups of patients with an OS of 12.66 months in those patients who achieved CR or PR vs 2.4 months in non-responders (p0.000). Patients relapsed after alloSCT (7 patients) presented a poor outcome (median OS was 1.6 months).